What drove Soleno's revenue decline in 2024?

Soleno Therapeutics experienced a significant decline in revenue in 2024, with reported revenue being zero for the quarter ended December 31, 2024. Although the exact details of the revenue decline are not available, we can infer some potential factors from related information: 1. **Lack of Product Launch**: Soleno's lead product candidate, DCCR, was under FDA review for treating Prader-Willi syndrome. The lack of FDA approval and subsequent commercial launch activities may have contributed to the revenue decline. 2. **Financial Position**: Soleno's financial position was strengthened with the secure loan and security agreement with Oxford Finance, which provided up to $200 million in financing. However, the need for a loan agreement may indicate that the company did not have sufficient cash flow for its anticipated commercial launch activities, potentially leading to a revenue decline. In conclusion, Soleno's revenue decline in 2024 was likely driven by a combination of factors including lack of product launch and financial position. |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |SLNO|SLNO.O|Soleno Therapeutics|2023 Q1|-45.98183088749126|-8356000|186| |SLNO|SLNO.O|Soleno Therapeutics|2023 Q2|-26.022304832713754|-8475000|186| |SLNO|SLNO.O|Soleno Therapeutics|2023 Q3|-77.12002609262883|-1.0861E7|186| |SLNO|SLNO.O|Soleno Therapeutics|2023 Q4|-105.9059423988334|-1.1296E7|186|